Literature DB >> 34261433

Review of applications of CRISPR-Cas9 gene-editing technology in cancer research.

Ziyi Zhao1, Chenxi Li1, Fei Tong2, Jingkuang Deng1, Guofu Huang3, Yi Sang4.   

Abstract

Characterized by multiple complex mutations, including activation by oncogenes and inhibition by tumor suppressors, cancer is one of the leading causes of death. Application of CRISPR-Cas9 gene-editing technology in cancer research has aroused great interest, promoting the exploration of the molecular mechanism of cancer progression and development of precise therapy. CRISPR-Cas9 gene-editing technology provides a solid basis for identifying driver and passenger mutations in cancer genomes, which is of great value in genetic screening and for developing cancer models and treatments. This article reviews the current applications of CRISPR-Cas9 gene-editing technology in various cancer studies, the challenges faced, and the existing solutions, highlighting the potential of this technology for cancer treatment.
© 2021. The Author(s).

Entities:  

Keywords:  CRISPR; Cancer; Cancer treatment; Cas9; High throughput screening

Year:  2021        PMID: 34261433     DOI: 10.1186/s12575-021-00151-x

Source DB:  PubMed          Journal:  Biol Proced Online        ISSN: 1480-9222            Impact factor:   3.244


  96 in total

Review 1.  Genome editing with engineered zinc finger nucleases.

Authors:  Fyodor D Urnov; Edward J Rebar; Michael C Holmes; H Steve Zhang; Philip D Gregory
Journal:  Nat Rev Genet       Date:  2010-09       Impact factor: 53.242

2.  Targeting DNA double-strand breaks with TAL effector nucleases.

Authors:  Michelle Christian; Tomas Cermak; Erin L Doyle; Clarice Schmidt; Feng Zhang; Aaron Hummel; Adam J Bogdanove; Daniel F Voytas
Journal:  Genetics       Date:  2010-07-26       Impact factor: 4.562

Review 3.  Assembly and function of RNA silencing complexes.

Authors:  Erik J Sontheimer
Journal:  Nat Rev Mol Cell Biol       Date:  2005-02       Impact factor: 94.444

4.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

5.  CRISPR gene-editing tested in a person for the first time.

Authors:  David Cyranoski
Journal:  Nature       Date:  2016-11-24       Impact factor: 49.962

Review 6.  Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.

Authors:  Chang Liu; Li Zhang; Hao Liu; Kun Cheng
Journal:  J Control Release       Date:  2017-09-11       Impact factor: 9.776

Review 7.  Cornerstones of CRISPR-Cas in drug discovery and therapy.

Authors:  Christof Fellmann; Benjamin G Gowen; Pei-Chun Lin; Jennifer A Doudna; Jacob E Corn
Journal:  Nat Rev Drug Discov       Date:  2016-12-23       Impact factor: 84.694

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 9.  CRISPR/Cas9 and cancer targets: future possibilities and present challenges.

Authors:  Martyn K White; Kamel Khalili
Journal:  Oncotarget       Date:  2016-03-15

Review 10.  Targeted genome editing in acute lymphoblastic leukemia: a review.

Authors:  Adrián Montaño; Maribel Forero-Castro; Jesús-María Hernández-Rivas; Ignacio García-Tuñón; Rocío Benito
Journal:  BMC Biotechnol       Date:  2018-07-17       Impact factor: 2.563

View more
  1 in total

1.  A peptide derived from the N-terminus of charged multivesicular body protein 6 (CHMP6) promotes the secretion of gene editing proteins via small extracellular vesicle production.

Authors:  Junyu Fan; Jiajie Pan; Xiaozhe Zhang; Yixi Chen; Yue Zeng; Lihan Huang; Dongwei Ma; Ziqi Chen; Guifu Wu; Wendong Fan
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.